An interventional study of Exablate Prostate Treatment in Prostate Cancer, sponsored by InSightec. Active, not recruiting at 5 sites in United States. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.
Sponsored by InSightec · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Neoplasms by InSightec — none open to participants now, 1 under way, none of them phase 3. Prostatic Neoplasms · InSightec.
Among the 10 studies in Prostatic Neoplasms by InSightec, this one is the 7th largest by enrollment, is the only one that started in 2019, is one of 7 with no phase, and was the 10th registered.
7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.
Browse Prostatic Neoplasms studies →None of the 10 studies in Prostatic Neoplasms by InSightec is open now. The open studies under Prostatic Neoplasms, anywhere →
Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 50 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2019.
This study's enrollment of 14 is below the median of 60 across 5,353 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 44 across the 10 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
InSightec is the lead sponsor of 84 studies on the registry; 9 are open to participants now.
1 of the studies in Prostatic Neoplasms by InSightec that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03998657InSightecContinued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Neoplasms by InSightec, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This extended clinical investigation is a multicenter, prospective, single arm study intended to provide continued access of the Exablate Model 2100 device (Exablate Prostate) to patients for treatment of prostate lesions and collect additional safety and effectiveness data during the 510(k) preparation and review period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with Exablate Prostate 2100 Type-3 System
Device: Exablate Prostate Treatment
The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.
Also known as: Exablate Prostate, Exablate MRgFUS
Incidence and severity of device/procedure-related complications following treatment
Safety will be evaluated by incidence and severity of device/procedure-related complications following treatment. Adverse events will be recorded and categorized according to severity and relationship to the biopsy procedure, the Exablate procedure, or to the Exablate device. They will be classified based on body system, severity, and frequency.
Time frame: 12 months
Proportions of treated subjects reporting negative Gleason 7 biopsy within the prostate biopsy treatment area.
Effectiveness will be evaluated by targeted lesion control based on biopsy results. Proportions of treated subjects reporting negative Gleason 7 biopsy within the treatment area and/or MRI verification of index lesion(s) ablation. PSA results and validated subject-reported questionnaires will be summarized.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2019 (actual). Primary completion is estimated for Dec 2026, 84 months after the start.
Of 57 industry-sponsored interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 84 months is above that.
Counting every sponsor, half of 1,157 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.